• Home
• Conference Coverage
• Event Calendar
• UroToday International Journal
• Advanced Search

UroToday's Sexually Transmitted Disease section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of sexually transmitted diseases. Also available are conference coverage for all timely science on sexually transmitted diseases, audio podcasts and downloadable slides from UroToday's slide library. Online Urology & Urologic Oncology Journal Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.

Search    Display 5 10 15 20 25 30 50 results per page Results 106 - 110 of 110 << Start < Prev 1 2 3 4 5 6 7 8 Next > End >> U.S. FDA Okays Glaxo's Valtrex to Prevent Herpes Transmission Friday, 29 August 2003 WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved GlaxoSmithKline's drug Valtrex (valacyclovir) for use in preventing transmission of genital herpes. read more Officials Aim to Combat Jump in Sexually Transmitted Diseases in the Netherlands Wednesday, 25 June 2003 AMSTERDAM - Dutch health officials, alarmed at an "explosive" increase in sexually transmitted infections in the Netherlands, say they will change tactics to combat the trend. read more Sexual Health Crisis Looms in Britain, Politicians Say Tuesday, 10 June 2003 LONDON (Reuters Health) - Britain is facing a sexual health crisis with diseases like chlamydia, syphilis and gonorrhoea soaring, a parliamentary committee said on Wednesday. read more Tuberculosis Risk Depends on Duration of HIV Infection Tuesday, 10 June 2003 NEW YORK (Reuters Health) - Findings from a study of HIV-positive injecting drug users (IDU) in Europe indicate that the risk of tuberculosis varies according to the duration of HIV infection. The risk is highest 4 to 6 years and 9 years after infection. read more Pyrazinamide More Toxic Than Expected in Treatment of TB Friday, 06 June 2003 NEW YORK (Reuters Health) - The incidence of major adverse reactions to the antituberculosis drug pyrazinamide (PZA) is higher than for other first-line agents, results of a study conducted at the Montreal Chest Institute in Quebec suggest. read more Resource Center Editor's Top Picks We are pleased to introduce the new "Editor's Picks" section designed to highlight the most exciting breaking science and hottest news in Urology!   << Start < Prev 1 2 3 4 5 6 7 8 Next > End >> Results 106 - 110 of 110

UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 About The Editors | About Us | Contact Us | Report an Inaccuracy | Sponsorship Opportunities | Terms of Use Privacy Policy | © 2009 UroToday ® All Rights Reserved